3.3. Increased Frequency of Nerve Growth Factor Receptor (NGFR)-Positive Cells is Accompanied with Suppression of MITF-Dependent Program in the Majority of Melanoma Cell Lines Resistant to Vemurafenib or Trametinib. This evidence concerns the gene MITF and melanoma.